Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4466MR)

This product GTTS-WQ4466MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ4466MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15859MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ9669MR IVTScrip™ mRNA-Anti-CD19&CD3E, JNJ-64052781(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64052781
GTTS-WQ6048MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO 136
GTTS-WQ8236MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ14115MR IVTScrip™ mRNA-Anti-NGF, aNGF75(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aNGF75
GTTS-WQ6168MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ15955MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ11004MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MCLA-117
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW